Simultaneous curative resection may improve the long-term survival of patients diagnosed with colorectal liver metastases: A propensity score–matching study
Xianmao Shi(Guangxi Medical University), Weizhong Tang(Guangxi Medical University), Tao Luo(Guangxi Medical University), Hualin Wu(Guangxi Medical University), Shun Lü(Shanghai Jiao Tong University), Jie Chen(Jiangsu University), Qingyuan Zhang(Harbin Medical University), Xiaobo Wang(Centre National de la Recherche Scientifique), Chunliu Huang(Sun Yat-sen University)
Cited by 2
Related Papers
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|1.7k
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
|The Lancet Oncology|2015|1.6k
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial
|The Lancet Oncology|2016|1.2k
Overall Survival with Osimertinib in Resected <i>EGFR</i> -Mutated NSCLC
|New England Journal of Medicine|2023|605